Barry will also join the company’s board of directors, where Lucier will continue to serve as board chair and aid in transition efforts, the San Diego-based company said.
NuVasive also said that it promoted current strategy, tech and corp dev exec VP Matt Link to president. Link has worked with NuVasive since 2006, holding numerous roles in the company primarily around building the US commercial organization.
In his role with Medtronic, Barry leads the company’s second largest business with $5.5 billion in annual revenue, NuVasive said, leading more than 14,000 employees in 78 countries. Prior to joining Medtronic, Barry held commercial and leadership roles at Covidien.
“On behalf of the board of directors, I want to thank Greg for his many contributions to NuVasive—first as a member of the board, and then as our chairman and CEO. Greg quickly shaped NuVasive into a global spine systems innovator, delivering highly differentiated technologies and procedurally integrated solutions to the market, improving patient outcomes by enabling better clinical decision-making and execution. We look forward to continuing to work with Greg, leveraging his business leadership and industry expertise as chairman of the board. Succession planning is one of the most important responsibilities for a board of directors of a publicly traded company, and we take those responsibilities seriously. Through our comprehensive recruitment efforts, we were impressed with Chris’s expertise in the medical device industry, and feel his strong reputation as a skilled and strategic operator, along with his innate passion and business know-how, will enable him to continue NuVasive’s transformation of spine surgery, adding tremendous value as he leads NuVasive into the future,” board lead independent director Don Rosenberg said in a press release.
“Chris has successfully led teams globally, managed complex R&D programs, driven commercial initiatives and executed strategic acquisitions. He has built a stellar reputation for driving employee engagement and operational excellence. Through my personal and professional interactions with Chris, it is clear to me his leadership will benefit our surgeon partners, employees and shareholders. As a board member and shareholder, I have every confidence in Chris’s ability to take NuVasive to its next level of growth,” Lucier said in a prepared release.
Prior to joining the Dublin, Ohio-based company, Crawford served as chief operating officer of healthcare, education and business dining for Aramark.
“We are thrilled to welcome Victor to the organization as he brings a wealth of direct experience with many of our customers and clearly understands the complexities of global supply chain management in the healthcare arena. His strategic focus on customer relationships and in-depth knowledge of institutional management systems will help us build on the success of the various components of our pharmaceutical business including Specialty Solutions, Nuclear and Pharmaceutical Distribution,” Kaufmann said in a prepared statement.
Bigfoot Biomedical said yesterday it named former Unilife (NSDQ:UNIS) COO Ian Hanson as its new chief technology officer and ex-Abbott (NYSE:ABT) exec Jyoti Palaniappan as its new chief commercial officer.
Prior to joining Milpitas, Calif.-based Bigfoot, Hanson served as senior VP and COO of Unilife, leading development on their wearable injector platform and drug delivery systems. Prior to joining Unilife, he held positions with Medtronic’s diabetes business.
“I’m very excited about the impact Bigfoot is going to have in this space. This team has a drive and energy that sets it apart, with the background and expertise to realize a category-defining vision,” Hanson said in a prepared statement.
Palaniappan previously served 11 years with Abbott, leading the US commercial operations of its diabetes business. Prior to Abbott, he held positions at Thermo Fisher (NYSE:TMO) and consulted with McKinsey & Company, Bigfoot Biomedical said.
“It is amazing to see over 100,000 people following Bigfoot on Facebook already, patiently waiting for Bigfoot products to launch. I am truly humbled and energized to join this passionate team who are working hard to get Bigfoot’s patient-centered designed, innovative products into the hands of people with insulin-requiring diabetes as quickly as possible,” Palaniappan said in a press release.
“Ian and Jyoti bring with them an impressive depth of experience in drug delivery systems, device development, and health technology commercialization. I’m thrilled by what Jyoti and Ian will add to the Bigfoot team and eager to see them apply their tangible passion and deep expertise to our vision for an easier, safer, and better life for people with diabetes,” co-founder & CEO Jeffrey Brewer said in a prepared release.
IRRAS said today that its senior VP of commercial operations and European GM Karl-Matthias Moehlmannhas left the company.
The Stockholm-based company announced that its executive management team now consists of prez & CEO Kleanthis Xanthopoulos, CFO and deputy CEO Fredrik Alpsten, CCO Will Martin, product dev VP Lance Boling and human capital senior director Kellie Fontes.
IRRAS said that its extended management group consists of product excellence VP Adam Sampson, product development senior director Dino De Cicco, regulatory & quality director Dessi Lyakov and finance VP Sabina Berlin.
Prior to joining Clearside, Crawford served as supply chain and customer service VP with Pharma Tech Industries, and has held various management positions with companies including Abbott, Allergan (NYSE:AGN), Aronex Pharma, Immucor, Shionogi and Zenith Goldline Pharma, the Alpharetta, Ga.-based company said.
“Thomas brings an important depth of manufacturing operations and supply chain management experience to the company. Thomas will be in a position to provide seamless distribution management for suprachoroidal CLS-TA to many of our global testing sites and, if suprachoroidal CLS-TA is approved, in support of our commercial supply,” CEO & prez Daniel White said in a prepared statement.